Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06669091 · ClinicalTrials.gov registry record · Phase 1
Food-effect Study of Ecopipam Pharmacokinetics
A Phase 1 study, sponsored by Emalex Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT06669091 is a Phase 1 study that has completed, run by Emalex Biosciences. The registered enrollment target is 25 participants.
The verdict
NCT06669091, a Phase 1 study, has completed, sponsored by Emalex Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Standard food-effect study to identify the effect of food on ecopipam pharmacokinetics after administration of a to-be-marketed ecopipam tablet in healthy volunteers.
Interventions
- DRUG Ecopipam tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-11-05 |
| Est. Completion | 2024-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06669091
The ClinicalTrials.gov registry entry for NCT06669091 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emalex Biosciences, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ecopipam tablet is the first listed.
NCT06669091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06669091 about?
NCT06669091 is a clinical study titled "Food-effect Study of Ecopipam Pharmacokinetics". Standard food-effect study to identify the effect of food on ecopipam pharmacokinetics after administration of a to-be-marketed ecopipam tablet in healthy volunteers.
What is the current status of trial NCT06669091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2024-11-05. Estimated completion is 2024-12-27.
What interventions are being tested in trial NCT06669091?
The interventions under investigation include: Ecopipam tablet (DRUG).
Who is sponsoring clinical trial NCT06669091?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.